1-20 of 4,132 results for subject:"Side effects"
Librarians' tools
- Search time
- 0.491 seconds
- Solr query time
- 0.009 seconds
- Search query
- subject:"Side effects"
- We searched for
- subject_t:"Side effects" OR subject_t:Side-effects OR subject_ses:93013
Type
House
Session
More
Year
More
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
To ask His Majesty's Government what discussions they have had with the Medicines and Healthcare products Regulatory Agency regarding the findings of an inquest at Norfolk Coroner's Court that a death by suicide was the result of side effects of finasteride; and what plans they have to commission further research on...
To ask His Majesty's Government what discussions they have had with the Medicines and Healthcare products Regulatory Agency regarding the findings of an inquest at Norfolk Coroner's Court that a death by suicide was the result of side effects of finasteride; and what plans they have to commission further research on...
Lords motion to approve. Amendment to regret debated and withdrawn. Original motion agreed to on question.
Lords motion to approve. Amendment to regret debated and withdrawn. Original motion agreed to on question.
My Lords, we must never lose sight of why we are here to debate these regulations. The infected blood scandal was a catastrophic failure of the state. It is a tragedy measured not only by the pain and suffering of its victims but by the decades it took for the...
My Lords, we must never lose sight of why we are here to debate these regulations. The infected blood scandal was a catastrophic failure of the state. It is a tragedy measured not only by the pain and suffering of its victims but by the decades it took for the...
Moved by
Baroness Brinton
Moved by
Baroness Brinton
My Lords, time is short not just for speakers in this debate, but increasingly so for the remaining victims of infected blood to get justice after one of the biggest ever failures by the British state on record. Curiously enough, all infected blood records are missing in Northern Ireland, for...
My Lords, time is short not just for speakers in this debate, but increasingly so for the remaining victims of infected blood to get justice after one of the biggest ever failures by the British state on record. Curiously enough, all infected blood records are missing in Northern Ireland, for...
My Lords, we must thank the noble Baroness, Lady Brinton, for her introduction to this amendment. Like others, I have had some desperately sad correspondence from widows whose husbands died relatively early after infection. Infection denied them children, some suffered serious discrimination within their family, some find that their husbands...
My Lords, we must thank the noble Baroness, Lady Brinton, for her introduction to this amendment. Like others, I have had some desperately sad correspondence from widows whose husbands died relatively early after infection. Infection denied them children, some suffered serious discrimination within their family, some find that their husbands...
My Lords, it is a great pleasure to follow the noble Baroness, Lady Finlay, and all the speakers in this debate thus far. I continue where she left off, taking a moment to look at the big picture.
We have a huge problem with trust in politics and government in our...
My Lords, it is a great pleasure to follow the noble Baroness, Lady Finlay, and all the speakers in this debate thus far. I continue where she left off, taking a moment to look at the big picture.
We have a huge problem with trust in politics and government in our...
My Lords, my mum Sheila Davies died from liver cancer in 2017 after a long battle with hepatitis. She did not drink, she never smoked, and I think she went out of the country a grand total of three times. In fact, she rarely ventured outside Plymouth, where she worked...
My Lords, my mum Sheila Davies died from liver cancer in 2017 after a long battle with hepatitis. She did not drink, she never smoked, and I think she went out of the country a grand total of three times. In fact, she rarely ventured outside Plymouth, where she worked...
My Lords, it is an honour to follow the noble Baroness. When one hears stories directly like that, they have an impact. I am so sorry for the noble Baroness’s loss. As ever, I have to declare my interest: one of my sister’s twin boys—my nephew, who was a haemophiliac—was...
My Lords, it is an honour to follow the noble Baroness. When one hears stories directly like that, they have an impact. I am so sorry for the noble Baroness’s loss. As ever, I have to declare my interest: one of my sister’s twin boys—my nephew, who was a haemophiliac—was...
My Lords, it is a pleasure to follow the noble Baroness. I want to mention in particular the contribution from the noble Baroness, Lady Davies of Devonport, who set out so powerfully the real-world consequences of this scandal: not just the infections but the stigma that went with them. I...
My Lords, it is a pleasure to follow the noble Baroness. I want to mention in particular the contribution from the noble Baroness, Lady Davies of Devonport, who set out so powerfully the real-world consequences of this scandal: not just the infections but the stigma that went with them. I...
I am deeply conscious of how much knowledge many noble Lords have on this topic, knowledge that has often been tragically accumulated through their own personal experiences and those of their families. I pay tribute to those, both in this House and outside it, who have done so much to...
I am deeply conscious of how much knowledge many noble Lords have on this topic, knowledge that has often been tragically accumulated through their own personal experiences and those of their families. I pay tribute to those, both in this House and outside it, who have done so much to...
My Lords, before I speak to the Motion to approve these regulations and to the regret amendment in the name of the noble Baroness, Lady Brinton, I want to begin by reflecting on the courage and tenacity of all infected and affected victims of the infected blood scandal. They have...
My Lords, before I speak to the Motion to approve these regulations and to the regret amendment in the name of the noble Baroness, Lady Brinton, I want to begin by reflecting on the courage and tenacity of all infected and affected victims of the infected blood scandal. They have...
My Lords, before I start, I put on record that I am in awe of the noble Baroness, Lady Davies, and her speech. I can only imagine how difficult it was for her to stand up and do that. She demonstrates what we have all listened to on many occasions:...
My Lords, before I start, I put on record that I am in awe of the noble Baroness, Lady Davies, and her speech. I can only imagine how difficult it was for her to stand up and do that. She demonstrates what we have all listened to on many occasions:...
I thank the Minister for her introduction to the SI and for the recent meeting. I will ask her many questions. If she cannot answer them all, I will look forward to hearing from her in due course. I have tabled this amendment because of very serious disquiet from infected...
I thank the Minister for her introduction to the SI and for the recent meeting. I will ask her many questions. If she cannot answer them all, I will look forward to hearing from her in due course. I have tabled this amendment because of very serious disquiet from infected...
My Lords, I thank the noble Baroness, Lady Davies of Devonport, for her very moving contribution about her mother’s own experience, reminding us of the consequences of stigma, hidden infections and diseases such as hepatitis not being identified, which meant that she could not be treated. I understand what it...
My Lords, I thank the noble Baroness, Lady Davies of Devonport, for her very moving contribution about her mother’s own experience, reminding us of the consequences of stigma, hidden infections and diseases such as hepatitis not being identified, which meant that she could not be treated. I understand what it...
To ask the Secretary of State for Health and Social Care, whether the Yellow Card adverse drug reaction reference GB-MHRA-MED-202605220730230940-NSQYR (linked to case file CEC 256289) is being actively reviewed by the clinical assessors of the Neurology, Pain and Psychiatry Expert Advisory Group as part of their current, ongoing safety...
To ask the Secretary of State for Health and Social Care, whether the Yellow Card adverse drug reaction reference GB-MHRA-MED-202605220730230940-NSQYR (linked to case file CEC 256289) is being actively reviewed by the clinical assessors of the Neurology, Pain and Psychiatry Expert Advisory Group as part of their current, ongoing safety...
The Medicines and Healthcare products Regulatory Agency (MHRA) confirms that in June 2026, the Neurology, Pain and Psychiatry Expert Advisory Group (NPPEAG) considered an assessment of clozapine drug level monitoring. The NPPEAG provided advice about the requirements for this type of monitoring. At present, clozapine drug-level monitoring is required only in specific clinical situations, partly because of the high level of variability between patients. The MHRA is taking forward the NPPEAG’s recommendations and will communicate to healthcare professionals once the regulatory position is finalised.
The review of clozapine drug-level monitoring focused on clinical and scientific data to establish the value of this type of monitoring in clinical practice. It took into account a range of information, including overall reporting patterns and themes in reports received through the Yellow Card scheme, but did not include clinical review of individual Yellow Card reports. MHRA safety assessments may also consider the views of patients and other stakeholders.
The MHRA will be launching a survey in the summer to gather information on awareness of key risks associated with clozapine, and to assess whether additional measures would be helpful for patients, their families, and carers, as well as healthcare professionals involved in the care of patients receiving clozapine.
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 6 July (HL1488), how the Medicines and Healthcare products Regulatory Agency will communicate the conclusions of its review of mental health risks for migraine prophylaxis medications; whether that Agency will consider a drug safety update or other national safety communication; and...
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 6 July (HL1488), how the Medicines and Healthcare products Regulatory Agency will communicate the conclusions of its review of mental health risks for migraine prophylaxis medications; whether that Agency will consider a drug safety update or other national safety communication; and...
The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department with responsibility for ensuring medicines meet appropriate standards of quality, efficacy, and safety.
The MHRA has plans to gather the currently available evidence on mental health and other related risks for licensed migraine prophylaxis medications, as referenced in the separate responses to questions HL1488 and HL1543. A formal timeline for this review has not yet been agreed, and consequently we are unable to provide an expected completion date at this stage.
The MHRA is committed to communicating any findings that may have implications for patient safety or the safe use of medicines. The MHRA will sometimes issue communications, such as drug safety updates, after the conclusion of a review. However, the review is at an early stage, and it would be premature to comment on any potential communication plans. In addition, any product information changes that may arise as a result of this review would be reflected in the published product information available at locations such as the MHRA website or the Electronic Medicines Compendium website.
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 6 July (HL1488), when they expect the Medicines and Healthcare products Regulatory Agency to complete its review of evidence on mental health and related risks for licensed migraine prophylaxis medications.
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 6 July (HL1488), when they expect the Medicines and Healthcare products Regulatory Agency to complete its review of evidence on mental health and related risks for licensed migraine prophylaxis medications.
The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department with responsibility for ensuring medicines meet appropriate standards of quality, efficacy, and safety.
The MHRA has plans to gather the currently available evidence on mental health and other related risks for licensed migraine prophylaxis medications, as referenced in the separate responses to questions HL1488 and HL1543. A formal timeline for this review has not yet been agreed, and consequently we are unable to provide an expected completion date at this stage.
The MHRA is committed to communicating any findings that may have implications for patient safety or the safe use of medicines. The MHRA will sometimes issue communications, such as drug safety updates, after the conclusion of a review. However, the review is at an early stage, and it would be premature to comment on any potential communication plans. In addition, any product information changes that may arise as a result of this review would be reflected in the published product information available at locations such as the MHRA website or the Electronic Medicines Compendium website.
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 7 July 2026 to Question 13788 on Migraines: Drugs, whether NHS England's processes for reviewing and identifying themes from Prevention of Future Deaths reports have identified (a) propranolol toxicity and (b) psychiatric adverse...
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 7 July 2026 to Question 13788 on Migraines: Drugs, whether NHS England's processes for reviewing and identifying themes from Prevention of Future Deaths reports have identified (a) propranolol toxicity and (b) psychiatric adverse...
Individuals or organisations receiving a coroner’s Prevention of Future Deaths (PFD) report have a statutory obligation to respond to the report and a deadline of 56 days to do so.
NHS England has processes in place to review and consider learning from PFD reports relevant to National Health Services. PFD reports may be considered alongside information from a range of sources, including patient safety incident data, clinical evidence, coroner recommendations, and medicines safety information from the Medicines and Healthcare products Regulatory Agency (MHRA).
Where PFD reports identify concerns relating to medicines, including potential toxicity or psychiatric adverse effects associated with preventive migraine treatments, these issues can inform patient safety activity and service improvement work as appropriate. The MHRA is responsible for monitoring the safety of medicines in the United Kingdom through the Yellow Card scheme and other pharmacovigilance processes, and works with partners across the health system to identify and assess emerging safety signals. NHS England and healthcare providers are expected to have regard to relevant safety advice issued by the MHRA.
To ask the Secretary of State for Health and Social Care, what steps he is taking to provide acknowledgement and redress to people who had faces damaged and developed serious side effects after retraction-extraction orthodontics during childhood.
To ask the Secretary of State for Health and Social Care, what steps he is taking to provide acknowledgement and redress to people who had faces damaged and developed serious side effects after retraction-extraction orthodontics during childhood.